Independent comparison · May 2026
Quick answer
Hims and Ro are the two largest direct-to-consumer telehealth platforms. Both offer GLP-1 weight loss programs as of 2026. Hims partnered with Novo Nordisk in 2026 to distribute brand-name Wegovy; Ro continues to offer both compounded options and brand-name access. Pricing is similar at ~$165–$200/month for compounded plans. Choice depends on whether you want brand-name (Hims) or compounded flexibility (Ro).
| Attribute | Hims | Ro |
|---|---|---|
| Founded | 2017 | 2017 |
| GLP-1 launched | 2024 | 2023 |
| Compounded option | No (since April 2026) | Yes |
| Brand-name option | Yes (Wegovy via Novo) | Yes |
| Compounded price | N/A | From $145/month |
| Brand price | Wegovy at $349/mo | Varies by plan |
| Insurance accepted | No | No |
| Coverage | All 50 states | All 50 states |
In April 2026, Hims discontinued its compounded semaglutide program and signed a distribution agreement with Novo Nordisk to sell brand-name Wegovy at $349/month. Existing compounded customers were migrated to Wegovy or refunded.
The shift made Hims the largest brand-name-only telehealth weight-loss platform but removed its lowest-priced option.
Ro continues to offer both compounded semaglutide and brand-name Wegovy through licensed pharmacy partners. Pricing for compounded starts around $145/month, with bundled plans for longer commitments.
Ro's 'Body' weight-loss subscription includes provider check-ins and lifestyle programming alongside the medication itself.
Choose Hims if you specifically want FDA-approved brand-name Wegovy, prefer the cleanest regulatory path, and the $349/month price works.
Choose Ro if you want compounded options for lower price, more flexibility on titration, or both compounded and brand-name access in case one supply tightens.
Several smaller providers in our review compete with both on price and beat them on per-criteria scoring. See the full comparison.
Independently rated providers that prescribe these medications, sorted by editorial score.
Comprehensive GLP-1 programs with board-certified physicians and lab monitoring
Excellent
150K+ members with 5 medication forms — injections, oral drops, lozenges, tablets, and pills
Very Good
The largest telehealth platform with GLP-1 programs
Fair
Since Hims discontinued compounded semaglutide in April 2026, no. Hims now sells only brand-name Wegovy at $349/month. Ro's compounded options start at $145/month.
Yes. Ro is a publicly accountable telehealth company founded in 2017, operates in all 50 states with licensed providers, and uses verified compounding pharmacies. See our independent Ro review for the full editorial scorecard.
No. Hims is cash-pay only. The $349/month Wegovy price is set through the Novo Nordisk direct distribution agreement.